medigraphic.com
ISSN 1025-0298 (Digital)
ISSN 1025-028X (Impreso)

2016, Número 3

<< Anterior

VacciMonitor 2016; 25 (3)


Vacunas contra rotavirus: estado actual y tendencias futuras

Amin BN, Fernández CS

Idioma: Español
Referencias bibliográficas: 58
Paginas: 89-97
Archivo PDF: 123.61 Kb.


RESUMEN

Antes de la introducción de las vacunas contra el rotavirus en 2006, este patógeno era considerado la principal causa de gastroenteritis entre los niños menores de cinco años de edad, de todo el mundo. Las vacunas son una estrategia fundamental para proteger a los niños de la gastroenteritis severa por rotavirus. Actualmente existen dos vacunas comerciales disponibles Rotarix® y RotaTeq® y su aplicación está teniendo un impacto en la reducción en las hospitalizaciones y consultas, sin embargo, para los países pobres los costos para sostener un programa de inmunización son relativamente elevados. Existe además la preocupación de que la vacuna conlleve a la selección y difusión de cepas nuevas y antigénicamente diferentes que traigan consigo la disminución de eficacia de la vacuna. Para solventar estos aspectos los productores trabajan en la búsqueda de nuevas vacunas como es la vacuna de origen indio ROTAVAC®. Las autoridades sanitarias de varios países han implementado programas de vigilancia en hospitales centinelas para seguir la hospitalización debido a la gastroenteritis por rotavirus y conducir estudios para evaluar la efectividad e impacto de la vacuna.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, et al. 2008 estimate of worldwide rotavirus associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012;12(2):136-41.

  2. Steele AD, Madhi S, Cunliffe NA, Vesikari T, Phua KB, Lim F, et al. Incidence of rotavirus gastroenteritis by age in African, Asian and European children: Relevance for timing of rotavirus vaccination. Hum Vaccin Immunother 2016;12(9):2406-12. http://dx.doi.org/10.1080/21645515.2016.1179412

  3. de Oliveira LH, Camacho LA, Coutinho ES, Ruiz-Matus C, Leite JP. Rotavirus vaccine effectiveness in Latin American and Caribbean countries: A systematic review and meta-analysis. Vaccine 2015;33 Suppl 1:A248–54

  4. Sigei C, Odaga J, Mvundura M, Madrid Y, Clark AD, Kenya ProVac Technical Working G, et al. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda. Vaccine 2015;33 Suppl 1:A109-18.

  5. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, et al. Effi cacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo controlled trial. Lancet 2010;376:615-23.

  6. Chai PL, Lee WS. Out-of-pocket costs associated with rotavirus gastroenteritis requiring hospitalization in Malaysia. Vaccine 2009;27S:F112-15. doi:10.1016/j.vaccine.2009.08.069

  7. World Health Organization. Global Rotavirus Information and Surveillance Bulletin. Geneva: WHO; 2013.

  8. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneumonia and diarrhoea. Lancet 2013;381:1405-16.

  9. Staat MA, Azimi PH, Berke T, Roberts N, Bernstein DI, Ward RL, et al. Clinical presentations of rotavirus infection among hospitalized children. Ped Infect Dis J 2002; 21:221-7

  10. Estes M. Rotaviruses and their replication. En: Fields BN, Knipe DM, Howley PM. Virology 4th ed. Vol. 2. Philadelphia: Lippincott–Raven; 2001. p.1747–86.

  11. Kapikian AZ, Hoshino Y, Chanock RM. Rotaviruses. En: Fields BN, Knipe DM, Howley PM. Virology 4th ed. Vol. 2. Philadelphia: Lippincott–Raven, 2001. p.1787–1833.

  12. Matthijnssens J, Ciarlet M, Rahman M, Attoui H, Bányai K, Estes MK, et al. Recommendations for the classifi cation of group A rotaviruses using all 11 genomic RNA segments. Arch Virol 2008;153:1621–29.

  13. Gentsch JR, Woods PA, Ramachandran M, Das BK, Leite JP, Alfi eri A, et al. Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. J Infect Dis 1996;174 Suppl 1:S30-6.

  14. Cunliffe NA, Bresee JS, Gentsch JR, Glass RI, Hart CA. The expanding diversity of rotaviruses. Lancet 2002;359:640-2.

  15. O’Ryan M. Vacunas anti-rotavirus: Al fi n una realidad. Rev Chil Infect 2005;22(4):345-54.

  16. Tra My PV, Rabaa MA, Vinh H, Holmes EC, Hoang NV, Vinh NT, et al. The Emergence of Rotavirus G12 and the Prevalence of Enteric Viruses in hospitalized Pediatric Diarrheal Patients in Southern Vietnam. Am J Trop Med Hyg 2011;85(4):768-75. doi:10.4269/ajtmh.2011.11-0364

  17. Sharma S, Paul VK, Bhan MK, Patrima R. Genomic characterization of nontypeable rotaviruses and detection of a rare G8 strain in Delhi, India. J Clin Microbiol 2009;47:3998- 4005.

  18. Mullick S, Mandal P, Nayak MK, Ghosh S, De P, Rajendran K, et al. Hospital based surveillance and genetic characterization of rotavirus strains in children (<5 years) with acute gastroenteritis in Kolkata, India, revealed resurgence of G9 and G2 genotypes during 2011–2013. Vaccine 2014;32 Suppl 1:A20-8. doi: 10.1016/j.vaccine.2014.03.018.

  19. Das BK, Gentsch JR, Hoshino Y, Ishida S, Nakagomi O, Bhan MK, et al. Characterization of the G serotype and genogroup of New Delhi newborn rotavirus strain 116E. Virology 1993;197:99- 107.

  20. Estes MK, Morris AP. A viral enterotoxin. A new mechanism of virus induced pathogenesis. Adv Exp Med Biol 1999;473:73-82.

  21. World Health Organization. Rotavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2013;88:49-64.

  22. Widdowson MA, Steele D, Vojdani J, Wecker J, Parashar U. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines. J Infect Dis 2009;200:S1-8.

  23. Bresee J, Fang ZY, Wang B, Nelson EAS, Tam J, Soenarto Y et al. First report from the Asian Rotavirus Surveillance Network. Emerg Infect Dis 2004;10:988-95.

  24. Lin CL, Chen SC, Liu SY, Chen KT. Disease Caused by Rotavirus Infection. Open Virol J 2014;8:14-19.

  25. Velasquez D, Parashar UD, Jiang B. Strain diversity plays no major role in the varying effi cacy of rotavirus vaccines: An overview. Infect Genet Evol 2014;28:561-71.

  26. de la Cruz F, Guzmán MG, Esquivel M, Grandio O, Vázquez S, Bravo J. Clinical and epidemiologic aspects of acute diarrhea caused by rotavirus in children. Cuba 1982-1984. Rev Cubana Med Trop 1990;42(2):178-87.

  27. Ribas MA, Fernández D, Rodríguez C, Toraño I, Pimentel T. Evaluación de un Dot ELISA para la detección de antígeno de Rotavirus. Rev Cubana Med Trop 1996;48(1).

  28. Aguiar P, Rojas O, Ribas MA. Proporción de casos esporádicos de diarreas agudas causadas por rotavirus del grupo A en Cuba, julio-noviembre, 2006. Rev Cubana Hig Epidemiol 2009;47(2).

  29. Pérez J, Valdés-Dapena M, Rodríguez O, Torres K, Piñeiro E. Diarrea Aguda por Rotavirus en niños hospitalizados. Hospital Pediátrico Docente ¨Juan Manuel Márquez¨. 2012. Panorama Cuba y Salud 2015;10(1):39-43.

  30. Cunliffe N, Dove W, Bunn J, Ben Ramadam M, Nyangao J, Riveron R, et al. Expanding global distribution of rotavirus serotype G9: Detection in Libya, Kenya, and Cuba. Emerg Infect Dis 2001;7:890-92.

  31. Ribas MA, Nagashima S, Calzado A, Acosta G, Tejero Y, Cordero Y et al. Emergence of G9 as a Predominant Genotype of Human Rotaviruses in Cuba. J. Med Virol 2011;83(4):738-44.

  32. Ribas MA, Tejero Y, Cordero Y, León MA, Rodríguez M , Pérez- Lastre J. Detection of rotavirus and other enteropathogens in children hospitalized with acute gastroenteritis in Havana, Cuba. Arch Virol 2015;160(8):1923-30.

  33. Bowen MD, Mijatovic-Rustempasic S, Esona MD, Teel EN, Gautam R, Sturgeon M, et al. Rotavirus Strain Trends during the Post-Licensure Vaccine Era: United States, 2008-2013. J Infect Dis 2016;214(5):732-8.

  34. Center for Disease Control. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. MMWR 1999;48:1-20.

  35. Kapikian AZ, Hoshino Y, Chanock RM, Perez-Schael I. Effi cacy of a quadrivalent rhesus rotavirus–based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 1996;174 Suppl 1:S65–72.

  36. Center for Disease Control. Withdrawal of rotavirus vaccine recommendation. MMWR 1999;48:1007.

  37. Peter G, Myers MG. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 2002;54:110.

  38. Rothman KJ, Young-Xu Y, Arellano F. Age dependence of the relation between reassortant rotavirus vaccine (RotaShield) and intussusception. J Infect Dis 2006;193(6):898. doi: 10.1086/500217.

  39. World Health Organization Report of GACVS meeting of 11-12 December 2013. WHO Wkly Epidemiol Rec 2014;89:53–60.

  40. Center for Disease Control. Prevention of Rotavirus Gastroenteritis Among Infants and Children Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2009;58:1-25.

  41. Gandhi G. Charting the evolution of approaches employed by the Global Alliance for Vaccines and Immunizations (GAVI) to address inequities in access to immunization: a systematic qualitative review of GAVI policies, strategies and resource allocation mechanisms through an equity lens (1999–2014). BMC Public Health 2015;15:1198. doi 10.1186/s12889-015- 2521-8.

  42. Bar-Zeev N, Kapanda L, Tate JE, Jere KC, Iturriza-Gomara M, Nakagomi O, et al. Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study. Lancet Infect Dis. 2015;15(4):422-8.

  43. World Health Organization. Global Rotavirus Information and Surveillance Bulletin. Geneva: WHO; 2012.

  44. Santos V, Marques DP, Martins-Filho PRS, Cuevas LE, Gurgel RQ. Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and metaanalysis. Infect Dis Poverty 2016;5:83. doi 10.1186/ s40249-016-0173-2.

  45. Patel M, Steel D, Parashar U. Infl uence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines Vaccine 2012;30 Suppl 1:A30-5. doi: 10.1016/j. vaccine.2011.11.093.

  46. E Clarke, Desselberger U. Correlates of protection against human rotavirus disease and the factors infl uencing protection in low-income settings. Mucosal Immunology 2015;8:1-17. doi:10.1038/mi.2014.114.

  47. World Health Organization. Full report of GACVS meeting of 11-12 June 2014. WHO Wkly Epidemiol Rec 2014;89:321-36

  48. Dang DA, Nguyen VT, Vu DT, Nguyen TH, Nguyen DM, Yuhuan W, et al. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children. Vaccine 2012;30 Suppl 1:A114-21.

  49. Bines JE, Danchin M, Jackson P, Handley A, Watts E, Lee KJ, et al. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, doubleblind, placebo-controlled trial. Lancet Infect Dis 2015;15(12):1389- 97. doi: 10.1016/S1473-3099(15)00227-3.

  50. Nelson EA, de Quadros CA, Santosham M, Parashar UD, Steele D. Overcoming perceptions of fi nancial barriers to rotavirus vaccine introduction in Asia. Hum Vaccin Immunother 2013;9(11):2418-26.

  51. Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, et al. Effi cacy of a monovalent human bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet 2014;383:2136-43.

  52. Fu C, He Q, Xu J, Xie H, Ding P, Hu W, et al. Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children. Vaccine 2012;31(1):154-8.

  53. Glass RI,. Bhan MK, Ray P, Bahl R,. Parashar UD, Greenberg H, et al. Development of Candidate Rotavirus Vaccines Derived from Neonatal Strains in India. J Infect Dis 2005;192:S30–5.

  54. Bhan MK, Glass RI, Ella KM, Bhandari N, Boslego J, Greenberg HB, et al. Team science and the creation of a novel rotavirus vaccine in India: a new framework for vaccine development. Lancet 2014;383:2180-3. http://dx.doi.org/10.1016

  55. Bhandari N, Sharma P, Glass RI, Ray P, Greenberg H, Taneja S, et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine 2006;24:5817-23.

  56. Bhandari N, Sharma P, Taneja S, Kumar T, Rongsen-Chandola T, Appaiahgari B, et al. A Dose-Escalation Safety and Immunogenicity Study of Live Attenuated Oral Rotavirus Vaccine 116E in Infants: A Randomized, Double-Blind, Placebo- Controlled Trial. J Infect Dis 2009;200:421-9.

  57. Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, et al. Effi cacy of a monovalent human bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine 2014;32 Suppl 1:A110-6.

  58. John J, Kawade A, Rongsen-Chandola T, Bavdekar A, Bhandari N, Taneja S, et al. Active surveillance for intussusception in a phase III effi cacy trial of an oral monovalent rotavirus vaccine in India. Vaccine 2014;32 Suppl 1:A104-9.




2020     |     www.medigraphic.com